Nyxoah SA (NYXH) Q3 2026 Earnings Call Highlights
Nyxoah SA (NYXH) reported Q3 2026 revenue of EUR9.2M, up 365% YoY. CEO Liam Kelly highlighted U.S. market opportunities, adjusted FY 2026 revenue guidance to EUR33M-EUR35M, and progress in CCC PMA supplement submission. The company trained 80 new surgeons and activated 53 new accounts. CMS reimbursement for Genio procedure increased by 11-13%. Cash position was EUR77.1M as of Q3 2026.
How this was made
The 30-second read
Why it matters
The earnings release provides fresh quantitative data and strategic updates that were not previously public.
Market read
First disclosure of Nyxoah's quarterly performance and guidance; relevant for traders tracking med‑tech and sleep‑apnea device stocks.
What to watch
Potential reimbursement increase from CMS final rule could improve long‑term profitability.
Background
Nyxoah SA (NYXH) reported Q3 2026 results, highlighted successful pivotal study, FDA PMA supplement filing, and updated guidance.
Ticker impact
Q3 2026 earnings call disclosed net revenue of EUR9.2M, updated full-year 2026 revenue guidance to EUR33-35M and gross margin guidance to 60-62%, plus FDA PMA supplement submission.
likely modest pressure as guidance was lowered versus prior expectations, but strong revenue growth may support upside.
First report of quarterly results and guidance; market will price in lower revenue outlook while noting strong margin improvement.
Market effects
Positive data for the sleep‑apnea device sector may lift peers, but guidance downgrade could temper enthusiasm.
European med‑tech investors may reassess exposure to NYXH.
Limited to niche medical‑device niche; broader market impact minimal.
Counterpoint
Despite guidance cut, the rapid revenue growth and margin expansion suggest upside if the U.S. launch accelerates.
Key entities
- ExecutiveLiam Kelly
CEO of Nyxoah, provided commentary on launch and guidance.
- ExecutiveLoic Moreau
Interim CFO, disclosed financial metrics.
